Table 2.
Incidences of BPAR and other outcomes according to TAC-IPV and RM/NRM status.
| Low-IPV/NRM(n = 452) | High-IPV/NRM(n = 375) | Low-IPV/RM(n = 106) | High-IPV/RM(n = 147) | P-value | |
|---|---|---|---|---|---|
| Overall BPAR (n, %) | 64 (14.2%)†§ | 82 (21.9%)* | 19 (17.9%) | 47 (32.0%)* | <0.001 |
| Acute TCMR (n, %) | 53 (11.7%)§ | 66 (17.6%) | 16 (15.1%) | 37 (25.2%)* | 0.001 |
| Active ABMR (n, %) | 13 (2.9%)§ | 16 (4.3%) | 40 (3.8%) | 15 (10.2%)* | 0.003 |
| Chronic active TCMR (n, %) | 6 (1.3%) | 3 (0.8%) | 0 (0.0%) | 1 (0.7%) | 0.584 |
| Chronic active ABMR (n, %) | 5 (1.1%)†§ | 16 (4.3%)* | 0 (0.0%) | 7 (4.8%)* | 0.003 |
| De novo DSA positive (n, %) | 49 (10.8%) | 46 (12.3%) | 12 (11.3%) | 23 (15.7%) | 0.477 |
| CNI toxicity (n, %) | 68 (15.0%) | 58 (15.5%) | 15 (14.2%) | 34 (23.1%) | 0.106 |
| BK virus nephropathy (n, %) | 11 (2.4%) | 18 (4.8%) | 4 (3.8%) | 5 (3.4%) | 0.333 |
Categorical variables are shown as proportions. *P <0.0083 versus low-IPV/NRM group, †P <0.0083 versus high-IPV/NRM group, §P <0.0083 versus high-IPV/RM group.
ABMR, antibody-mediated rejection; BPAR, biopsy-proven allograft rejection; CNI, calcineurin inhibitor; DSA, donor-specific antibody; IPV, intra-patient variability; NRM, non-rapid metabolizer; RM, rapid metabolizer; TAC, tacrolimus; TCMR, T-cell mediated rejection.